Research and Markets: High Level of Competition between Emerging and ... 4-traders (press release) The RA market contains several of the most profitable therapies across the entire drug industry. Humira (adalimumab), Rituxan (rituximab) Remicade (infliximab) and Enbrel (etanacept) globally generated revenues of $9.3 billion, $7.2 billion, $6.1 ... |
